Exatecan Mesylate - CAS 169869-90-3
Catalog number: 169869-90-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Exatecan Mesylate (DX-8951) is a totally synthetic analogue of the topoisomerase I-inhibitor camptothecin, which was synthesised to impart increased aqueous solubility, greater tumour efficacy, and less toxicity than camptothecin itself.
DX8951f; DX 8951f; DX-8951f
Canonical SMILES:
1.Camptothecins: a review of their chemotherapeutic potential.
Ulukan H;Swaan PW Drugs. 2002;62(14):2039-57.
Camptothecin analogues and derivatives appear to exert their antitumour activity by binding to topoisomerase I and have shown significant activity against a broad range of tumours. In general, camptothecins are not substrates for either the multidrug-resistance P-glycoprotein or the multidrug-resistance-associated protein (MRP). Because of manageable toxicity and encouraging activity against solid tumours, camptothecins offer promise in the clinical management of human tumours. This review illustrates the proposed mechanism(s) of action of camptothecins and presents a concise overview of current camptothecin therapy, including irinotecan and topotecan, and novel analogues undergoing clinical trails, such as exatecan (DX-8951f), IDEC-132 (9-aminocamptothecin), rubitecan (9-nitrocamptothecin), lurtotecan (GI-147211C), and the recently developed homocamptothecins diflomotecan (BN-80915) and BN-80927.
2.DX-8951f: summary of phase I clinical trials.
De Jager R;Cheverton P;Tamanoi K;Coyle J;Ducharme M;Sakamoto N;Satomi M;Suzuki M;DX-8931f Investigators Ann N Y Acad Sci. 2000;922:260-73.
Exatecan mesylate (DX-8951f) is a new hexacyclic camptothecin analogue with favorable attributes compared to topotecan and CPT-11, including watersolubility, greater potency against topoisomerase I, lack of esterase-dependent activation, broad antitumor activity, and low cross-resistance against MDR-1 overexpressing tumors. In preclinical studies, the compound demonstrated a favorable toxicology profile with hematologic dose-limiting toxicity and moderate gastrointestinal toxicity, linear pharmacokinetics, P450 hepatic metabolism (CYP3A4 and CYP1A2), and predominately fecal excretion. The results of six U.S. and European phase I clinical trials as well as two Japanese studies are presented including total DX-8951 and lactone DX-8951 pharmacokinetics. The toxicity profile was similar for all schedules of administration. Hematologic toxicity was dose-dependent and reversible. Neutropenia was dose-limiting in minimally pretreated patients, whereas neutropenia and thrombocytopenia were dose-limiting in heavily pretreated patients. Non-hematologic toxicity included moderate gastrointestinal toxicity (nausea, vomiting > diarrhea), transient elevation of hepatic transaminases, asthenia, and alopecia.
3.Gateways to clinical trials.
Bayes M;Rabasseda X;Prous JR Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 3-AP, Adalimumab, adefovir dipivoxil, AeroDose albuterol inhaler, agalsidase alfa, alemtuzumab, aminolevulinic acid methyl ester, anidulafungin, anthrax vaccine, anti-CTLA-4 MAb, azimilide hydrochloride; Bevacizumab, BG-12, bimatoprost, bortezomib, bosentan, botulinum toxin type B; Caspofungin acetate, ceftobiprole, certolizumab pegol, CG-53135, cilansetron; Darbepoetin alfa, degarelix acetate, dimethylfumarate, duloxetine hydrochloride, dutasteride; Eicosapentaenoic acid/docosahexaenoic acid, eletriptan, entecavir, esomeprazole magnesium, exatecan mesilate, exenatide, ezetimibe; Falecalcitriol, fampridine, fondaparinux sodium, fontolizumab; Gefitinib, gepirone hydrochloride; Human insulin; IDEA-070, imatinib mesylate, iodine (I131) tositumomab; Lanthanum carbonate, lubiprostone; Mafosfamide cyclohexylamine salt, melatonin; NC-531, nemifitide ditriflutate, neridronic acid, nolatrexed dihydrochloride; Oral insulin; Palifermin, parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, plerixafor hydrochloride, posaconazole, pramlintide acetate, pregabalin, PT-141; Quercetin; Ranibizumab, renzapride hydrochloride, RSD-1235; Sabarubicin hydrochloride, semapimod hydrochloride, Semax, SHL-749; Tegaserod maleate, tenatoprazole, tetrodotoxin, tolevamer sodium, trabectedin, travoprost, travoprost/timolol; Valdecoxib, visilizumab, Xcellerated T cells, XP-828L; Zoledronic acid monohydrate.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Topoisomerase Products

CAS 252979-56-9 Banoxantrone dihydrochloride

Banoxantrone dihydrochloride
(CAS: 252979-56-9)

Banoxantrone dihydrochloride, a bioreductive prodrug, can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor, and ex...

CAS 65271-80-9 Mitoxantrone

(CAS: 65271-80-9)

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certai...

CAS 119413-54-6 Topotecan Hydrochloride

Topotecan Hydrochloride
(CAS: 119413-54-6)

Topocecan is a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes top...

CAS 86639-52-3 SN-38

(CAS: 86639-52-3)

SN-38 is the active metabolite of irinotecan. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN...

CAS 529488-28-6 GENZ-644282

(CAS: 529488-28-6)

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibi...

CAS 123948-87-8 Topotecan

(CAS: 123948-87-8)

Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions. ...

CAS 136572-09-3 Irinotecan Hydrochloride Trihydrate

Irinotecan Hydrochloride Trihydrate
(CAS: 136572-09-3)

The hydrochloride salt of Irinotecan. Irinotecan is a prodrug that can be activated to 7-ethyl-10-hydroxy-camptothecin (SN-38) by the carboxylesterase-convertin...

CAS 213819-48-8 Belotecan hydrochloride

Belotecan hydrochloride
(CAS: 213819-48-8)

Belotecan hydrochloride, also called as CKD-602 hydrochloride, a Topoisomerase I inhibitor, is the hydrochloride salt of the semi-synthetic and water-soluble ca...

Chemical Structure

CAS 169869-90-3 Exatecan Mesylate

Quick Inquiry

Verification code

Featured Items